Jan 21, 03:00 PM

Federal Circuit Clarifies Patent Law: Gene Editing Safe Harbor, Prior Art in IPRs, Orange Book Listings, and Novartis Patent Decision

Recent rulings from the Federal Circuit have clarified important aspects of patent law. A district court has determined that factual disputes prevent the application of the Safe Harbor provision to gene editing technology at the pleading stage. Additionally, the Federal Circuit confirmed that published patent applications are considered prior art in inter partes reviews (IPRs) as of their filing date. In a related decision, the court stated that a patent listed in the Orange Book must specifically claim the active ingredient to be deemed proper. Furthermore, the Federal Circuit reversed a previous patent decision involving Novartis and affirmed deterrence sanctions in another case. These rulings highlight ongoing developments in patent litigation and regulatory compliance.

#Federal Circuit #Safe Harbor #Orange Book #Novartis

Written with ChatGPT (GPT-4o mini).

Sources

Additional media

Image #1 for story federal-circuit-clarifies-patent-law-gene-editing-safe-harbor-prior-art-iprs-433f3988

Image #2 for story federal-circuit-clarifies-patent-law-gene-editing-safe-harbor-prior-art-iprs-433f3988